Loading company…
Vaxart develops oral recombinant vaccines for viral diseases.
Vaxart develops oral recombinant vaccines intended to provide mucosal and systemic immunity against viral diseases. Its vaccine programs target COVID-19, norovirus, influenza, and human papillomavirus (HPV). The company is based in San Francisco, US, and is at the Series C stage. In February 2018, it completed a reverse merger with Aviragen Therapeutics Inc.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in